Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis a...
June 02 2017 - 08:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that CAT-5571, a novel
activator of autophagy, will be presented as a potential treatment
for cystic fibrosis in an oral presentation at the 40th European
Cystic Fibrosis Society (ECFS) Conference. The ECFS Conference is
being held June 7 – June 10, 2017, in Seville, Spain, at the
Conference and Exhibition Center of Seville FIBES II.
Feng Liu, Ph.D., Associate Director at Catabasis, will give an
oral presentation titled “CAT-5571: An Autophagy Activator That
Enhances the Clearance of Intracellular Bacteria” during the
session “Novel strategies for treatment of Cystic Fibrosis
pathogens” on Thursday, June 8, 2017 from 5:00pm – 6:30pm local
time.
About CAT-5571Catabasis is developing CAT-5571 as a
potential oral treatment for cystic fibrosis (CF) with potential
effects on both the cystic fibrosis transmembrane conductance
regulator (CFTR) and on the clearance of Pseudomonas aeruginosa.
CAT-5571 is a small molecule that activates autophagy, a process
that maintains cellular homeostasis and host defense mechanisms,
and is known to be impaired in CF. Catabasis has shown in
preclinical studies that CAT-5571, in combination with
lumacaftor/ivacaftor, enhances cell-surface trafficking and
function of CFTR with the F508del mutation. Catabasis has also
shown that CAT-5571 enhances the clearance of P. aeruginosa
infection in preclinical models of CF.
About Cystic FibrosisCystic fibrosis (CF) is a rare,
chronic, genetic, life-shortening disease that affects over 70,000
patients worldwide, predominantly in the Caucasian population. In
CF, a malfunctioning cystic fibrosis transmembrane conductance
regulator (CFTR) ion channel impairs chloride secretion, with
deleterious effects on multiple organs, and particularly
devastating effects on pulmonary, intestinal and pancreatic
function. Patients affected with CF are also predisposed to
respiratory failure caused by persistent lung infections that are
difficult to treat with standard antibiotics. Advancements in
research and treatments have extended the life expectancy for those
living with CF, however there is currently no cure.
About CatabasisAt Catabasis Pharmaceuticals, our mission
is to bring hope and life-changing therapies to patients and their
families. Our SMART (Safely Metabolized And Rationally Targeted)
linker drug discovery platform enables us to engineer molecules
that simultaneously modulate multiple targets in a disease. We are
applying our SMART linker platform to build an internal pipeline of
product candidates for rare diseases and plan to pursue
partnerships to develop additional product candidates. For more
information on the Company's drug discovery platform and pipeline
of drug candidates, please visit www.catabasis.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170602005073/en/
Investor and Media ContactCatabasis
Pharmaceuticals, Inc.Andrea Matthews,
617-349-1971amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Feb 2024 to Mar 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Mar 2023 to Mar 2024